



# PRESS RELEASE

**FOR IMMEDIATE RELEASE**

## **Med 7, LLC announces grant of US Patent for Clinical Use.**

BLUFFDALE, Utah, January 15, 2024 — Med 7, LLC ([www.med7cbd.com](http://www.med7cbd.com)) announces the recent granting of a US patent for Hempzorb81™, marking a significant milestone in the field of inflammation management. This groundbreaking patent highlights Med 7® as the first Full Spectrum CBD product to receive such recognition for its efficacy in addressing inflammation-related conditions.

The comprehensive data within the patent underscores the transformative impact of Med 7® on inflammatory markers, particularly in reducing circulating levels of key indicators such as tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6). Impressively, regular consumption has been shown to decrease these inflammatory markers by as much as 25 to 50% or more. Additionally, markers signaling the presence of ongoing inflammation, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), have demonstrated reductions of up to 10 to 25% or more. The patent focuses specifically on treating patients with COVID-19 (SARS-CoV-2) with Med 7®, a full-spectrum hemp product made with Purzorb® technology, now trademarked as Hempzorb81™.

*"We understand the pivotal role that inflammation plays in various diseases and the aging process. The ability of Med 7 to naturally and safely mitigate inflammation without the associated risks of serious side effects positions it as a revolutionary solution in the medical landscape," said Matt Smith, CEO of Med 7.*

*"We believe that the granting of this US patent for Med 7 is a testament to our shared dedication to advancing health and well-being and offering cutting-edge, non-pharmaceutical options."*

### **About Med 7**

Med 7® is a technology-driven company that markets and distributes health and wellness products to medical professionals. Hempzorb81™ is a full spectrum hemp product made with Purzorb® technology, which mimics the body's natural process of absorption by converting oil-based nutrients into water-soluble products. Hempzorb81™ is patent pending for other human health conditions.

To view the complete patent: 11826320 ([uspto.gov](https://www.uspto.gov))

**Med 7, LLC**

801-577-4223

[med7cbd.com](http://med7cbd.com)

[public.relations@Med7usa.com](mailto:public.relations@Med7usa.com)